Use of pegylated interferon alpha 2a as an add-on therapy in chronic hepatitis B patients on tenofovir disoproxil fumarate facilitates rapid reductions in hepatitis B surface antigen (HBsAg) and core-related antigen (HBcrAg) levels, a study has shown.
Inflammatory bowel disease (IBD) is associated with a heightened risk of urolithiasis both before and after diagnosis, a study has found. This association is especially pronounced in patients exposed to anti-tumour necrosis factor (anti-TNF) therapy and those who have undergone surgery, suggesting that IBD severity and surgery contribute to a risk increase.
Among medications used to treat chronic constipation, bisacodyl appears to be the most effective in increasing the frequency of bowel movements, while plecanatide results in the lowest increase in the number of spontaneous bowel movements (SBMs) and complete (C)SBMs, according to a study, which provides data that may be valuable to medication guidelines for treating the said condition.
In the treatment of patients with Crohn’s disease refractory to anti-tumour necrosis factor, ustekinumab is superior to vedolizumab in terms of steroid‐free remission and treatment persistence outcomes in both the induction and maintenance phases, as shown in the results of a comparative study.
In managing functional dyspepsia, itopride and acotiamide, tricyclic antidepressants, histamine‐2 receptor antagonists, proton pump inhibitors, and the antipsychotic sulpiride or levosulpiride all prove to be more effective than placebo, according to the results of a meta-analysis.